FORE's lead asset, plixorafenib, is a Class I/V600 and II BRAF inhibitor with demonstrated clinical safety and early efficacy signals in the previous Phase I/IIa clinical trial. The USA-based company's proprietary functional genomics platform is allowing FORE to optimize drug development by identifying existing compounds with known clinical profiles and a clear path through clinical development to advance new medicines for patients without adequate treatment options.